#LCSM Chat Topic 4/2/2020: #COVID19 and #LungCancer

It seems that the world has turned upside down.  At the time I write this, there have been almost 550,00 cases of COVID-19 confirmed in the world and over 85,000 in the US.  Here in New York City there have been over 23,000 cases and 365 deaths as of March 27th (https://coronavirus.jhu.edu/map.html). The pandemic has placed enormous stress on our health care delivery system.  For lung cancer patients, it has affected healthcare providers’ ability to perform tests and radiologic procedures; provide timely diagnosis, staging, and care for early stage patients; and, in… Read More

#LCSM Chat Topic 3/5/2020: Expanding Access to Cancer Clinical Trials

Cancer research is necessary if we are to find more durable treatments for all cancers. While research has come a long way, we still have a long way to go in order to establish quality, durable treatments for many diagnosed with advanced/metastatic disease.  Typically research begins, “at the bench” with cell lines and in organoids. Once an idea has shown some promise, it often moves on to testing in animals. When an idea, test or therapeutic shows significant promise, it must move to clinical trials. Clinical trials, allow diagnostic tests, screening methods,… Read More

#LCSM Chat 2020-02-06: Dealing with #lungcancer stigma and nihilism

  All too often, lung cancer patients encounter stigma towards their disease and nihilism towards their chances of beating it. Although the causal connection between tobacco smoking and lung cancer was heavily emphasized in well intended public campaigns designed to curb cigarette use, unintended consequences arose. Perhaps more than any other cancer, lung cancer is automatically associated with a bad personal choice – smoking. Many people believe patients could have avoided their lung cancer had they made better decisions. Such perceptions may stifle discussions about lung cancer, cause patients to refuse screening… Read More